Monatsschrift Kinderheilkunde, Journal Year: 2023, Volume and Issue: unknown
Published: Dec. 2, 2023
Clinical Microbiology and Infection, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Language: Английский
Citations
0
Pediatric Pulmonology, Journal Year: 2024, Volume and Issue: 59(5), P. 1498 - 1501
Published: Jan. 30, 2024
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by authors. Any queries (other than missing content) should be directed to corresponding author article.
Language: Английский
Citations
2
Clinical Microbiology and Infection, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 1, 2024
Language: Английский
Citations
1
The Pediatric Infectious Disease Journal, Journal Year: 2023, Volume and Issue: 43(3), P. 242 - 249
Published: Dec. 25, 2023
Background and objectives: In June 2022, the mRNA COVID-19 vaccination was recommended for young children. We examined clinical characteristics factors associated with status among vaccine-eligible children hospitalized acute COVID-19. Methods: enrolled inpatients 8 months to <5 years of age community-acquired across 28 US pediatric hospitals from September 20, 2022 May 31, 2023. assessed demographic factors, including highest level respiratory support, defined as unvaccinated, incomplete, or complete primary series [at least 2 (Moderna) 3 (Pfizer-BioNTech) vaccine doses ≥14 days before hospitalization]. Results: Among 597 children, 174 (29.1%) patients were admitted intensive care unit 75 (12.6%) had a life-threatening illness, 51 (8.5%) requiring invasive mechanical ventilation. Children underlying neurologic/neuromuscular conditions more frequently received higher support. Only 4.5% (n = 27) completed their 7.0% 42) initiated but did not series. 528 unvaccinated nearly half 251) previously healthy, them required extracorporeal membrane oxygenation 1 died. Conclusions: Most COVID-19, most despite being eligible. Nearly these no conditions. Of small percentage who series, it hospitalization.
Language: Английский
Citations
3
Vaccine, Journal Year: 2024, Volume and Issue: 44, P. 126550 - 126550
Published: Nov. 26, 2024
Language: Английский
Citations
0
Transboundary and Emerging Diseases, Journal Year: 2024, Volume and Issue: 2024(1)
Published: Jan. 1, 2024
The African swine fever virus (ASFV) has the ability to infect both wild boars and domestic pigs, regardless of their breeds or ages, often resulting in a mortality rate 100%. Host innate immunity is most important defense weapon against invasion pathogenic microbial infection. cGAS‐STING signaling pathway one greatest discoveries twenty‐first century, which crucial host’s immune response. Recent studies have found that interaction between cGAS/STING ASFV plays key role during At same time, also evolved different strategies evade killing host promote its survival. Here, we review latest progress infection, pathways, related molecular mechanisms, aiming provide new ideas for further research on pathogenesis ASFV, development vaccines therapeutic drugs.
Language: Английский
Citations
0
The Pediatric Infectious Disease Journal, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 8, 2024
The introduction of messenger ribonucleic acid (mRNA) vaccine technology represents a significant breakthrough in immunology and public health, offering novel approach to combat infectious diseases. Unlike traditional vaccines that often use inactivated pathogens or protein subunits, mRNA strand RNA instruct cells produce specific viral protein, triggering an immune response without exposing the patient actual virus. This innovative has several key advantages over classical methods. Rapid Development Production can be designed produced much faster than vaccines.1,2 do not require time-consuming resource-intensive cultivation eggs cells. Instead, once genetic sequence pathogen is known, scientists quickly synthesize corresponding laboratory. Scalability production process for highly scalable, allowing rapid mass pandemics emerging diseases.1 same platform used manufacture different by simply changing construct. Precision Flexibility precisely target antigens pathogen, enhancing specificity effectiveness response.1 precision also allows development multivalent protect against multiple strains types pathogen. Safety Profile Since live virus, there no risk causing disease vaccinated individual.1,2 Additionally, rapidly degraded body, minimizing long-term side effects. coronavirus 2019 (COVID-19) pandemic demonstrated potential vaccines, leading deployment mRNA-based COVID-19 vaccines. These have shown high efficacy favorable safety profile, paving way further research application technology. are very powerful tools new threats as modeling studies regarding demonstrated. review will explore current landscape emphasizing recent advances their implications pediatric use. such Moderna's mRNA-1273 Pfizer-BioNTech's BNT162b2, received emergency authorization from United States Food Drug Administration 2020. Both profile clinical trials both adolescents younger children. A newly developed vaccine, mRNA-1283, improved antigen expression, antibody responses, stability at refrigerated temperatures.3 phase 3 study being conducted booster dose. Clinical Trials Adolescents (12–15 Years) BNT162b2 showed 100% mild moderate adverse events (AEs) resolving within 1–2 days.4 Similarly, 90% approximately 40% preventing asymptomatic infection.5 Children (5-11 90.7% with similar older groups.6 88.0% during Delta variant era.7 Younger (6 Months–5 2–3 trial 36.8%–50.6% Omicron period.8 73.2% mostly AEs.9 Real-world Data significantly reduce severe disease, hospitalization, intensive care unit hospitalizations death due COVID-19.10 There been evidence remain effective prevention symptomatic children caused lineage variants many countries.11–13 meta-analysis 2-dose reduced acute respiratory syndrome 2 infections, multisystem inflammatory reactogenicity profiles.14 Serious AEs were rare, including myocarditis (1.8 per million) which generally resolved few days. An additional reported low incidence rate vaccine-associated myopericarditis young adults early outcomes, though ongoing monitoring recommended.15 It important note differing vaccination policies recommendations across countries, widely depending on presence absence factors economic opportunity costs. World Health Organization prioritized high-risk groups, healthy emphasized recommended.16 Bivalent Vaccine emerged November 2021, its sublineages (including BA.4, BA.5, XBB, BA.2.86, EG.5, etc) now dominant circulating worldwide.16 was more transmissible included lineages greater evade vaccine-induced immunity previous variants. encoded represented original well representing BA.4/5 variant. assessed bivalent aged 5–17 years.17 54.0% infection 49.4% COVID-19. concludes effectively adolescents, importance staying up date recommended vaccinations. Maternal Vaccination For protecting unvaccinated infants under 6 months, maternal anticipated. One found pregnancy reduces COVID-19–related hospitalization less months.18 (2 doses vaccine; mRNA-1273) infant 52% overall, 80% delta period, 38% omicron period. highlights protective benefits infants. Furthermore, associated lower risks neonatal admission intrauterine fetal death, increased peripartum outcomes.19 Long COVID Patients may experience health problems referred post-acute sequelae "long COVID," brain fog, dyspnea, gastrointestinal dysfunction, generalized pain fatigue. large retrospective effect long years age.20 Other Vaccines Recognizing technology, prominent biotechnology companies already numerous pipelines.2 Several currently trials. Respiratory Syncytial Virus syncytial virus (RSV) contagious causes bronchiolitis pneumonia. mRNA-1345 RSV consists single encoding stabilized prefusion F glycoprotein lipid nanoparticles Moderna surface required helping enter host exists states, postfusion. conformation potent neutralizing antibodies, sequences largely RSV-A RSV-B subtypes. 83.7% tract adults, based results.21 recently approval 60 age. In addition investigated fully enrolled, Phase 1 populations time writing this article. That assessing immunogenicity another "mRNA-1365" targeting human metapneumovirus (hMPV) participants 5 <24 months.21 Sanofi developing combination (SP0256) RSV, hMPV parainfluenza (PIV) (>60 age). Its 1/2 shows positive results boost RSV-neutralizing adults.22 However, Influenza Multiple influenza released since 2019. quadrivalent seasonal candidate (mRNA-1010) nucleoside-modified flu (BNT161) finished studies.23,24 exhibited robust responses all 4 strains, indicating advantage platform. yet adolescents. (SP0273). SP0273 higher compared licensed systemic reactions mRNA-1010 separate trial.22 Human Metapneumovirus cause co-circulating major subtypes (hMPV-A hMPV-B).25 Currently, treatments available hMPV. going into mRNA-1365 described section above. other mRNA-1653 PIV3. distinct full-length membrane-anchored fusion (F) proteins PIV3 co-formulated nanoparticle. essential entry induce strong humoral responses.26,27 18–49 years, tolerated immunogenic dose levels tested.28 1b randomized, observer-blind, placebo-controlled 12–59 months who seropositive Participants either 10 30 µg placebo, administered apart. levels, grade reported. Immunogenicity titers second did increase suggesting single-dose regimen effective.29 Epstein-Barr mononucleosis (IM), accounting IM cases annually. mRNA-1189 prevent IM. test safety, 12–30 age States. levels.30 Cytomegalovirus mRNA-1647 cytomegalovirus women childbearing evaluated 9–15 Five mRNAs encode subunits form membrane-bound pentamer complex, while sixth encodes B.1 Viruses Otherwise, pipelines, HIV, Zika rabies, varicella zoster, herpes simplex tuberculosis malaria highlighting critical future development.1,2 providing protection pertussis, brucella drug-resistant microorganism development. Estimation Non-COVID-19 provided valuable insights reasonable anticipate might occur given shared mechanisms. most frequently include symptoms injection site, fatigue, headache, muscle pain, chills, fever joint pain. typically resolve days consistent body's vaccination. instance, influenza, observed, mirroring those seen trials.21,23 CONCLUSIONS overview undergoing summarized Table 1. existing supports continued populations, ensure efficacy. progress holds great promise immunization, range TABLE - Overview Undergoing Target Pathogen Developer Age Status SARS-CoV-2 Pfizer-BioNTec mo Completed mRNA-1283 12 yr (5–18 yr), (2–<5 (5–<24 mo) 5–<24 EBV CMV 9 (16–40 1/2a (9–15 yr) indicates trials.CMV cytomegalovirus; EBV, virus; SARS-CoV-2, 2.
Language: Английский
Citations
0
Monatsschrift Kinderheilkunde, Journal Year: 2023, Volume and Issue: unknown
Published: Dec. 2, 2023
Citations
0